Cullinan Therapeutics Inc (CGEM)
$20.16
+0.25
(+1.26%)▲
Performance
- $19.71$20.70$20.16
2.23%
Downside
Day's Volatility :4.78%
Upside
2.61%
- $7.64$30.19$20.16
62.1%
Downside
52 Weeks Volatility :74.69%
Upside
33.22%
Returns
| Period | Cullinan Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -21.3% | 6.5% | 0.0% |
6 Months | 52.33% | 7.1% | 0.0% |
1 Year | 97.13% | 9.8% | 0.0% |
3 Years | -20.55% | 14.2% | -20.2% |
Highlights
Market Capitalization | 1.2B |
Book Value | $9.88 |
Earnings Per Share (EPS) | -3.07 |
Wall Street Target Price | 33.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -22.15% |
Return On Equity TTM | -29.47% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 18.9M |
EBITDA | -170.6M |
Diluted Eps TTM | -3.07 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.03 |
EPS Estimate Next Year | -3.06 |
EPS Estimate Current Quarter | -0.99 |
EPS Estimate Next Quarter | -0.85 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 63.69%
Technicals Summary
Sell
Neutral
Buy
Cullinan Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Cullinan Therapeutics Inc | 20.67% | 52.33% | 97.13% | -20.55% | 82172.73% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Cullinan Therapeutics Inc | 9.03 | NA | NA | -3.03 | -0.29 | -0.22 | NA | 9.88 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Cullinan Therapeutics Inc | Buy | $1.2B | 82172.73% | 9.03 | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Cullinan Therapeutics Inc
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 207.1%
Institutional Holdings
MPM Oncology Impact Management LP
13.27%Bvf Inc
5.55%Blue Owl Capital Holdings LP
5.07%Franklin Resources Inc
4.68%BlackRock Inc
4.21%Vanguard Group Inc
3.08%
Company Information
cullinan oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. sourced from the cullinan dry lab as well as external collaborators, cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.
Organization | Cullinan Therapeutics Inc |
Employees | 85 |
CEO | Mr. Nadim Ahmed |
Industry | Other Consumer Services |
Discover More
A Spac I Acquisition Corp
$20.16
+1.26%
Keyarch Acquisition Corp
$20.16
+1.26%
Connexa Sports Technologies Inc
$20.16
+1.26%
Us Value Etf
$20.16
+1.26%
First Wave Biopharma Inc
$20.16
+1.26%
Global X Msci Next Emerging
$20.16
+1.26%
Fat Projects Acquisition Corp
$20.16
+1.26%
Capital Link Global Fintech
$20.16
+1.26%
Applied Uv Inc
$20.16
+1.26%